insights_auto
Pse është rritur CRSP 5,85%?
Zhytu më thellëchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
53,39 US$
arrow_upward
+5,85%(+2,95) 1D
54,10 US$
arrow_upward
+1,33% (+0,71)bedtimeJashtë orarit
Mbyllur: 9 tet, 4:00:00 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për CRSP...
Hap
50,82 US$
I lartë
54,07 US$
I ulët
50,52 US$
Kapitalizimi i tregut
5,16 mld
Vëllimi mesatar
1,62 mln
Vëllimi
1,47 mln
Maksimumi 52-javor
78,00 US$
Minimumi 52-javor
44,12 US$
Fitimet për aksion
-4,76 US$
Beta
1,45
Aksionet në qarkullim
96,69 mln
Numri i punonjësve
393
Hap
50,82 US$
I lartë
54,07 US$
I ulët
50,52 US$
Kapitalizimi i tregut
5,16 mld
Vëllimi mesatar
1,62 mln
Vëllimi
1,47 mln
Maksimumi 52-javor
78,00 US$
Minimumi 52-javor
44,12 US$
Fitimet për aksion
-4,76 US$
Beta
1,45
Aksionet në qarkullim
96,69 mln
Numri i punonjësve
393
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Simply Wall Street
·
6 orë më parë
Upcoming CTX310 Data Could Test The Case For CRISPR Therapeutics Stock
Investing.com
·
7 orë më parë
Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics
MarketBeat
·
15 orë më parë
CRISPR Therapeutics (NASDAQ:CRSP) Shares Climb 5.7% - What's Next?
The Motley Fool
·
16 orë më parë
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Profili
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Rreth Crispr Therapeutics AG
Drejtori ekzekutivSamarth Kulkarni
Punonjësit393
Themeluar më2013
SeliaZug, Kantoni Zug, Zvicër
Sektori-
Uebsajticrisprtx.com